Welcome to our dedicated page for CLXT news (Ticker: CLXT), a resource for investors and traders seeking the latest updates and insights on CLXT stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CLXT's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CLXT's position in the market.
Calyxt (Nasdaq: CLXT), a plant-based synthetic biology company, announced its participation in two upcoming investor conferences. The H.C. Wainwright Global Investment Conference is scheduled for May 25, 2022, at 11:30 am ET, with a webcast available here. The LD Micro Invitational will take place on June 8, 2022, at 7:30 am ET, with the webcast accessible here. Presentations will be available for replay on Calyxt's website.
Calyxt, Inc. (Nasdaq: CLXT) reported its Q1 2022 results, highlighting significant advancements in its PlantSpring and BioFactory platforms. The company identified 28 molecules for development through customer demand, while successfully implementing AIML technologies to enhance production processes. Despite nominal revenue of $0 compared to $4.4 million in Q1 2021, Calyxt's net loss improved to $5.6 million from $10.0 million year-over-year. The recent underwritten stock offering generated $10 million, strengthening its balance sheet and enabling further investments in technology and customer relationships.
Calyxt, a plant-based synthetic biotechnology company (Nasdaq: CLXT), announced the hiring of two key executives to enhance its business development and manufacturing capabilities. Suellen Boot has been appointed as Business Development Director, bringing over 20 years of experience. Elizabeth Teigland joins as Manufacturing Director, with 15 years of expertise in chemistry and purification. These hires aim to facilitate the optimization of the BioFactory Production System and drive near-term revenue through partnerships and production scaling.
Calyxt, a plant-based synthetic biology company (Nasdaq: CLXT), will conduct a conference call on May 5, 2022, at 4:30 p.m. ET to discuss its first quarter financial results for the period ending March 31, 2022. The call will feature President and CEO Michael A. Carr and CFO Bill Koschak, followed by a Q&A session. Interested parties can access the call via a dedicated toll-free number or listen to a live broadcast online. A replay will be available for 30 days post-event. For more details, visit the company's website.
Calyxt, Inc. (Nasdaq: CLXT), a leader in plant-based synthetic biology, will engage in a fireside chat at the 34th Annual Roth Conference on March 15, 2022, at 3:00 p.m. ET (12:00 p.m. PT). The event will be held at the Ritz-Carlton in Dana Point, CA. A webcast of the chat will be available for viewing and replay on the company's website. Management will also be available for meetings during the conference. Calyxt focuses on innovative plant-based solutions that help customers achieve sustainability goals.
Calyxt, Inc. (Nasdaq: CLXT) announced its financial results for Q4 and fiscal year 2021, reporting revenues of $1.9 million in Q4, a sharp decline from $13.9 million in Q4 2020, attributed to the wind-down of its soybean product line. However, total revenue for 2021 rose to $26 million from $23.9 million in 2020, driven by higher commodity prices. The company reduced its net loss to $29.2 million in 2021, improving from $44.8 million in 2020, while cash and equivalents totaled $14.4 million as of December 31, 2021. Key developments included operationalizing its BioFactory and enhancing its AIML capabilities.
Calyxt, Inc. (Nasdaq: CLXT) will hold a conference call on March 3, 2022, at 4:30 p.m. EST to discuss its fourth quarter and full year results for 2021. The call will be led by CEO Michael A. Carr and CFO Bill Koschak, including a Q&A session. Participants are encouraged to join 5-10 minutes early. The call is accessible via dial-in numbers provided in the release, and a replay will be available through the company's website for 30 days. Calyxt focuses on plant-based synthetic biology products.
Calyxt, Inc. (NASDAQ: CLXT) announced the closing of its underwritten offering of 3,880,000 shares of common stock and warrants, resulting in net proceeds of approximately $10.0 million. The company plans to use these funds to enhance its BioFactory production system, expand its PlantSpring technology, and for general corporate purposes. Canaccord Genuity was the sole bookrunner for this offering, part of a previously filed shelf registration statement. This financial move aims to strengthen Calyxt's operational capabilities and customer relations.
Calyxt, Inc. (NASDAQ: CLXT) has announced an underwritten public offering of 3,880,000 shares of common stock and related warrants, aiming to raise approximately $10.9 million. Each share is priced at $1.41, and the offering includes pre-funded and common warrants that can potentially increase future share counts. Proceeds will fund enhancements to the company's BioFactory production system and PlantSpring technology platform, as well as working capital and general corporate purposes. The offering is expected to close around February 23, 2022.
Calyxt, a plant-based synthetic biotechnology company (Nasdaq: CLXT), announced the appointment of Gerry Nuovo as Senior Vice President of Business Development on February 7, 2022. With over 30 years of experience in the specialty chemicals and biotechnology sectors, Nuovo will focus on partnerships and transaction execution. CEO Michael A. Carr highlighted Nuovo's expertise aligns with Calyxt's strategy to deliver sustainable solutions in cosmetics and nutraceutical markets. Calyxt utilizes its proprietary PlantSpring™ technology and BioFactory™ production system to create innovative plant-derived compounds.